Search PubMed⌕ Search

Biomedical subjects

X Bosch

Publications and source records attributed to X Bosch.

At least 91 records · Page 5Linked to original sources
PubMed2000

[The efficacy of platelet IIb/IIIa receptor blockers in acute coronary syndromes].

The knowledge of the central role of platelets in the pathogenesis of acute coronary syndromes, on the one hand, and the fact that aspirin is a weak antiplatelet agent on the other, have led to an intensive investigational activity in antiplatelet drugs in the last years. Actually, the literature in the last two years is inundated with studies on the use of platelet IIb/IIIa receptor blockers in different clinical settings. Agents that block the IIb/IIIa platelet receptor have shown to be useful in improving prognosis of patients with acute coronary syndromes, especially in those undergoing percutaneous coronary revascularization procedures. However, their potential risk of bleeding and their high cost have prevented them from being applied universally and routinely. Furthermore there are still some unclear issues regarding the use of these drugs such as their correct dosage, the optimal duration of treatment and the direct comparison of the efficacy of different types of IIb/IIIa blockers available. On the other hand, oral IIb/IIIa antagonists have not improved the efficacy of aspirin to date and, moreover, they have been proven to be unsafe. Finally, it is necessary to identify those patients who will obtain the greatest benefit from the treatment in order to avoid the unnecessary risks and costs that would be derived from their universal use.

Acute Disease↗
PubMed2000

[Use of thrombolytic treatment in patients with acute myocardial infarction in Spain. Observations from the PRIAMHO study].

INTRODUCTION AND OBJECTIVES: Scarce information is actually available in our country regarding the use of thrombolytic treatment in patients with acute myocardial infarction and how consistently the recommendations of the clinical guidelines are being implemented. METHODS: Cohort study with one year follow-up of patients with acute myocardial infarction admitted in 24 Spanish hospitals in 1995. Differences in clinical characteristics and prognosis from patients treated with or without thrombolysis were compared. RESULTS: 2,191 of the 5,242 patients (42%) admitted with an acute myocardial infarction received thrombolytic therapy (range: 23%-63%). Reasons for exclusion in the rest were the absence of ST segment elevation (35%), contraindications (16%), prehospital delay >12 h (35%), and other causes (15%). Thrombolysis treated patients were at lower risk in general because they had shorter prehospital delays and were younger, more likely to be male, less frequently diabetic, with less prior history of angina or infarction. The average delay in administering therapy was of 3 hours while the average in-hospital delay was 50 minutes and depended only on the hospital where patients where admitted, as it was shorter in small centers. t-PA was administered in 49% of patients, streptoquinase in 46% and other drugs in 5%. Although t-PA was given more often to younger patients, smokers, anterior and Q-wave infarctions, and to patients with shorter prehospital delays, the determinant factor was the admission hospital with a frequency ranging from 9% to 96%. Patients not treated with thrombolytics had more complications during the acute phase, and required more invasive procedures. They also had a higher mortality at 28 days (17% vs. 10%, p < 0.0001) and at one-year follow-up (27% vs. 15%, p < 0.0001). Furthermore, a correlation was observed between mortality and delay of treatment application. In multivariate analysis, thrombolytic treatment was an independent predictor of survival at one year, with an odds ratio for mortality of 0.8 (95% CI: 0.66-0.96). CONCLUSIONS: Thrombolytic therapy in Spain does not yet conform to the recommendations of the actual guidelines for the treatment of patients with acute myocardial infarction because it is underused, especially in high-risk patients, the prehospital and in-hospital delays are too long, and a huge variability exists between hospitals in the frequency and delays of administration and selection of the drug that are not sufficiently explained by the characteristics of the patients. In spite of this, mortality of treated patients was 20% lower in comparison to the non-treated patients, after adjusting for the other clinical factors with demonstrated prognostic value.

Aged↗
PubMed2000

[In-hospital evolution and current prognosis of unstable angina].

INTRODUCTION AND PROGNOSIS: The prognosis of patients with unstable angina has improved in recent years resulting in a progressive reduction in hospital stay and treatment. The aim of this study was to know the current prognosis of patients with unstable angina in a non-selected population followed for up to 3 months. PATIENTS AND METHODS: 478 consecutive patients with unstable angina were studied. They were treated following a strict protocol and a management policy guided by symptoms and the results of an exercise test or a pharmacological stress test performed before hospital discharge. RESULTS: The mean age was 66 +/- 11 years with 30% being females. Thirty-five percent had a prior history of myocardial infarction, 61% presented ischemic changes on the admission ECG, and 16% had elevation of the CK-MB plasma levels. An echocardiogram was performed in 80% of the patients, a stress test in 62%, coronary angiography in 51%, and a revascularization procedure in 27% of the patients. During hospitalization, the incidence of mortality or myocardial infarction, refractory angina or ischemic complications was of 3.6%, 11% and 13%, respectively. After hospital discharge and during a 3-month follow-up, the incidence of these complications was of 3.3%, 9% and 10% (NS compared to the in-hospital period). Overall, from the time of hospital admission to the 3-month follow-up, 4.2% of the patients died, 7% died or had an infarction, 20% had refractory angina, and 26% had some ischemic complication. CONCLUSION: The in-hospital prognosis of unstable angina is currently good. However, patients discharged from hospital after stabilization, present an important number of ischemic complications during the following 3 months, similar to that presented by all patients during the acute phase.

Aged↗
PubMed2000

Feasibility and prognostic value of dobutamine-atropine stress echocardiography early in unstable angina.

BACKGROUND AND AIM: Because unstable angina has always been considered a contraindication for dobutamine-atropine stress echocardiography (DSE), the role of dobutamine-atropine stress echocardiography in unstable angina is unknown. Our aim was to assess the safety and prognostic value of dobutamine-atropine stress echocardiography in unstable angina. METHODS: One hundred and thirty-two patients were studied (mean age 64+/-12 years, 29 women). Dobutamine-atropine stress echocardiography was performed on the third day after hospital admission. End-points were unstable angina, myocardial infarction or cardiac death at 1 year follow-up. RESULTS: No major complications occurred during dobutamine-atropine stress echocardiography. Ninety-six (78%) patients were on beta-blocker therapy during the test; mean maximum heart rate achieved was 106+/-23 beats x min(-1). Nine of the 21 patients (43%) with a positive dobutamine-atropine stress echocardiography presented cardiac events during follow-up: two patients died, one had a myocardial infarction and six had recurrent class III-IV angina. Among 80 patients with negative dobutamine-atropine stress echocardiography, one (1%) had myocardial infarction and six patients (7.5%) had recurrent angina. Event-free survival after 1 year for patients with a negative dobutamine-atropine stress echocardiography for ischaemia was 91% compared to 57% for those with a positive dobutamine-atropine stress echocardiography (P<0. 0001). Left ventricular dysfunction (P=0.01), prior myocardial infarction (P=0.03) and a positive dobutamine-atropine stress echocardiography (P=0.004) were independent predictors of cardiac events during follow-up. CONCLUSIONS: Dobutamine-atropine stress echocardiography is safe in unstable angina if it is performed when patients remain asymptomatic for at least 48 h. A negative dobutamine-atropine stress echocardiogram for ischaemia predicts a good prognosis in medically treated patients with unstable angina and may allow their early discharge from hospital. Good prognostic information was obtained despite the use of beta-blockers and low heart rates during dobutamine-atropine stress echocardiography.

Adult↗
PubMed2000

Dobutamine stress echocardiography and exercise electrocardiography for risk stratification in medically treated unstable angina.

UNLABELLED: Previous reports have demonstrated the superiority of exercise echocardiography over exercise electro-cardiography (ex-ECG) for risk stratification in patients with medically stabilized unstable angina (UA). We sought to analyze the prognostic value of dobutamine stress echocardiography (DSE) compared with ex-ECG for risk stratification in patients with UA. METHODS: Ninety-two patients with medically treated UA were studied (mean age 65 +/- 11 years, 24 women, 42% of patients had electrocardiographic abnormalities on admission). Dobutamine stress echocardiography and treadmill ex-ECG were performed on the third day after hospital admission. End points were recurrent UA, myocardial infarction (MI), or cardiac death. RESULTS: Mean follow-up was 24 +/- 7 months. During follow-up, 22 patients had cardiac events (18 recurrent UA, 2 MI, 2 cardiac deaths). The event-free survival rate was 80% for patients with negative DSE results for ischemia and 52% for those with positive DSE results (log rank 9.57; P =.002), compared with an event-free survival rate of 79% for patients with negative ex-ECG results and 66% for those with positive ex-ECG results (log rank 2.06; P = not significant). Left ventricular dysfunction (P =.01) and a positive dobutamine stress echocardiogram (P =.03), but not a positive exercise electrocardiogram, were independent predictors of cardiac events during follow-up. CONCLUSIONS: Dobutamine stress echocardiography performed early in medically treated patients with UA predicts cardiac events during follow-up more accurately and with more specificity than ex-ECG does in this population.

Aged↗